Four-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions: The SPIRIT II Trial

Scot Garg, PWJC (Patrick) Serruys, K Miquel-Hebert

Research output: Contribution to journalArticleAcademicpeer-review

81 Citations (Scopus)


This report describes the 4-year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus-eluting stent (EES), or the TAXUS paclitaxel-eluting stent. At 4-year clinical follow-up, which was available in 256 (85.3%) patients, treatment with EES lead to a trend for lower rates of ischemia-driven major adverse cardiovascular events, a composite of cardiac death, myocardial infarction, and ischemia-driven target lesion revascularization (EES 7.7% vs. paclitaxel-eluting stent 16.4%, P = 0.056). Treatment with EES also resulted in a trend toward lower rates of cardiac death and numerically lower rates of myocardial infarction, ischemia-driven target lesion revascularization, and stent thrombosis. Overall, this study reports numerically fewer clinical events in patients treated with EES at 4-year follow-up, which is consistent with results from earlier follow-up. (C) 2010 Wiley-Liss, Inc.
Original languageUndefined/Unknown
Pages (from-to)1012-1017
Number of pages6
JournalCatheterization and Cardiovascular Interventions
Issue number7
Publication statusPublished - 2011

Research programs

  • EMC COEUR-09

Cite this